The CEO's total reported compensation of approximately $2.5 million is modest for a biotech company with a $2.8 billion market cap and is well within reasonable benchmarks for a CEO at this company size and stage. The compensation structure is well-designed: approximately 68% of the CEO's total pay is variable and at risk, consisting of performance-based annual bonuses (which paid out at 150% of target based on clearly disclosed and achieved corporate goals) and long-term stock options that only have value if the stock price rises. Kodiak's stock returned over 1,000% in the past year and +834% over three years, dramatically outperforming the XBI — SPDR S&P Biotech ETF, demonstrating strong alignment between executive pay and shareholder outcomes. The prior say-on-pay vote received 94% support, the company has a Dodd-Frank compliant clawback policy in place, and no policy red flags are present.

Non-audit fees of $2,000 represent only 0.17% of audit fees of $1,186,000, far below the 50% threshold that would raise independence concerns. PricewaterhouseCoopers is a Big 4 firm appropriate for a company of Kodiak's size and complexity. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire per policy. No material financial restatements are disclosed.